Novavax's full FDA approval for NUVAXOVID is a transformative milestone, unlocking a $175M Sanofi payment and validating ...

在经过为期六周的审评延迟后，美国FDA刚刚批准了诺瓦瓦克斯 (Novavax) 公司研制的新冠疫苗Nuvaxovid的上市许可，适用于65岁及以上人群以及12岁及以上伴有至少一种重症高风险基础疾病的人群。

The FDA has approved the Novavax COVID-19 vaccine, called Nuvaxovid, mainly for adults 65 or older, but people ages 12 to 64 ...

The FDA has approved Nuvaxovid to prevent COVID-19 in adults 65 years and older and high-risk individuals 12 through 64 years.

Nuvaxovid 由诺瓦瓦克斯与 赛诺菲 （Sanofi）合作开发，后者将根据里程碑协议向诺瓦瓦克斯支付 1.75 亿美元，未来还可能从疫苗销售中支付更多特许权使用费。 该制药商表示，FDA 批准了其针对 Nuvaxovid ...

近日，美国食品药品监督管理局（FDA）对诺瓦瓦克斯（Novavax）新一代新冠疫苗的审批决定引发行业关注。在经历延期后，FDA 最终以限制性条件批准该疫苗，同时 FDA 局长暗示即将调整疫苗审批框架，一系列动态为后疫情时代的疫苗监管政策走向埋下伏笔。

Novavax (NVAX.US) 获得美国食品药物管理局 (FDA)Covid-19疫苗的批准，将可与辉瑞 (PFE.US) 及莫德纳 (MRNA.US) 等对手竞争。该股周一早段抽升22%。

Previously granted Emergency Use Authorization, Nuvaxovid is now available for individuals over 12 years of age.

Novavax, Inc. (“Novavax”) announced that FDA approved its Biologics License Application (“BLA”) for Nuvaxovid™ for active ...

Key Takeaways Novavax received Food and Drug Administration approval for its new, protein-based COVID-19 vaccine.The shot, ...

Pharmaceutical giant Novavax on Monday announced that the U.S. Food and Drug Administration (FDA) approved its COVID-19 ...

Nuvaxovid is a recombinant protein-based COVID ... Jacobs, President and Chief Executive Officer, Novavax. Along with the approval, the FDA also requested Novavax conduct a phase 4 randomized ...